Bristol-Myers Squibb(US:BMY)2025-07-31 12:00Q2 2025 Performance - Global net sales reached approximately $12.3 billion, showing a 1% year-over-year increase, but 0% excluding foreign exchange impacts[11] - The Growth Portfolio net sales increased by 18%, or 17% excluding foreign exchange impacts[11] - GAAP earnings per share (EPS) were $0.64, while non-GAAP EPS reached $1.46, including a negative impact of $0.57 per share from acquired IPR&D charges[13] Financial Guidance - The company is adjusting its non-GAAP EPS guidance to $6.35 - $6.65[14] - Total revenues are expected to be approximately $46.5 billion - $47.5 billion[14] - The company is on track to pay down approximately $10 billion of debt by the end of Q2 2026, with approximately $6.5 billion already achieved as of Q2 2025[56] Strategic Business Development - The company executed strategic business development initiatives, including the formation of Immunology NewCo with Bain Capital[14,17] - A global alliance was formed to co-develop and co-commercialize BNT327 (PD-L1/VEGF bispecific)[18] - A license agreement was secured for exclusive worldwide rights to OncoACP3, strengthening the company's position in radiopharmaceuticals[18] Product Performance - Eliquis global net sales reached $3.68 billion, showing an 8% increase year-over-year, or 6% excluding foreign exchange impacts[46] - Reblozyl sales increased 34% to $568 million[41] - Opdivo sales increased 7% to $2.56 billion[36]